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Objectives. We assessed the abilities of two methods to measure
ejection fraction (EF)—radionuclide ventriculography (RVG) and
contrast left ventriculography (Cath-EFa) to predict cardiovascu-
lar events.
Background. Both RVG and Cath-EFa are commonly used
methods to measure left ventricular performance and assess
prognosis. Their comparative abilities to predict clinical events
have not been reported.
Methods. Both RVG EF and Cath-EFa were measured within 16
days of myocardial infarction (MI) in 688 patients. The results
were divided into terciles. Prognosis by terciles was assessed for
each technique. A multivariate analysis was performed to deter-
mine which EF measurement was a better predictor of prognosis.
Results. Average RVG–EF was 32% 6 7, while Cath-EFa was
42% 6 10. Both RVG and Cath-EFa were poorly correlated (R 5
0.42). Event rate declined across terciles with increasing EF for
both techniques (events in lowest to highest tercile of Cath-EFa
40.7%, 25.9%, 11.6%, p < 0.001; and RVG-EF 39.9%, 26.1%, 15.6%,
p < 0.001). There was concordance of terciles in 303 of 688
patients (44%). When patients in the highest RVG terciles were in
the highest Cath-EFa tercile, the event rate was 7%. However,
when patients in the highest RVG terciles were in the lowest
Cath-EFa tercile, the event rate was 19%. Both Cath-EFa (p <
0.001) and RVG-EF (p < 0.001) were independent predictors of
cardiovascular events.
Conclusions. Ejection fraction measured by RVG or during
catheterization is a valuable tool in the risk stratification of
postinfarct patients. When disagreement is present between clin-
ical impression and measurement by either method, the use of an
alternative measurement is warranted and complementary.
(J Am Coll Cardiol 1999;33:180–5)
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The presence of left ventricular (LV) dysfunction in the
postmyocardial infarction period has been recognized as an
important determinant of subsequent morbidity and mortality
(1–3). The degree of impairment of LV function can be
assessed using a variety of methods. End-diastolic volume,
end-systolic volume and ejection fraction (EF) have all been
described as important predictors of outcome in patients with
coronary artery disease (2–4). However, EF is the most widely
used clinical descriptor of LV function because of ease of
measurement and excellent reproducibility in patients with a
broad range of diagnoses. Ever since its description by Dodge
et al. in 1956 (5), LV function measured with contrast ven-
triculography has remained the gold standard against which
other techniques are judged. However, noninvasive techniques
for cardiac imaging are now in widespread use. One of the
most commonly used noninvasive techniques for measuring EF
is radionuclide ventriculography (RVG). In the time since its
initial application in the detection of wall-motion abnormali-
ties, RVG has become an important method for the quantifi-
cation of LV systolic function and its relation to future
cardiovascular events (6,7). The purpose of this study was to
determine the relationship and prognostic significance of two
methods of measuring EF in postmyocardial infarction (MI)
patients with LV dysfunction: RVG and contrast left ventricu-
lography.
Methods
All patients in this study were participants in the Survival
and Ventricular Enlargement (SAVE) study. Both the proto-
col and the results of SAVE have been published previously
(8,9). Eligible patients between the ages of 21 to 79 years, with
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an EF #40% by RVG, and who were between 3 to 16 days’
post-MI were randomly assigned to receive captopril or pla-
cebo. Patients were enrolled at 50 centers encompassing 110
hospitals. Out of 2,231 patients enrolled, 1,301 underwent
cardiac catheterization within 16 days of their MI. Out of this
group, 990 angiograms were submitted to the Cardiac Cathe-
terization Core Laboratory for analysis. Left ventriculograms
had been performed in 743 patients, but only 688 studies were
technically acceptable for quantitation of EF. Thus, the
present study is based on the final cohort of 688 SAVE study
patients who underwent technically acceptable contrast left
ventriculograms that were analyzed by the SAVE Cardiac
Catheterization Core Laboratory (G.L., G.F., S.S., G.M.).
Patients were followed for 2 to 5 years. The primary clinical
end point of the present analysis is cardiovascular mortality or
the first occurrence of severe heart failure during the mean
follow-up period of 3.5 years. Severe heart failure is defined as
a hospitalization for treatment of heart failure, or heart failure
severe enough to warrant discontinuation of blinded study
medication and initiation of open-label angiotensin converting
enzyme inhibitor therapy.
Assessment of RVG-EF. All patients underwent RVG
prior to enrollment in SAVE utilizing a standardized protocol.
The patient’s own red blood cells were labelled with
technetium-99. This was accomplished by intravenous injection
of 50 mg of stannous pyrophosphate. Fifteen minutes later,
10 cc of blood was withdrawn into a syringe containing 30 mCi
of technetium-99 pertechnetate and 1 ml of anticoagulant
citrate dextrose solution. The blood was incubated in the
syringe for 10 min, and then reinjected into the patient with
saline flush (10).
The RVG was performed with a gamma camera equipped
with a general, all-purpose, parallel hole collimator interfaced
with a dedicated computer. The energy window (20%) was set
over 120 keV. Image acquisition was done in the left anterior
oblique projection, and the anterior projection (45° to the right
of the angulation for the left anterior oblique projection). All
data were acquired in 64 3 64 matrix (word mode). At least 16
frames per electrocardiographic RR interval were acquired.
Each frame was ,40 ms. Unsmoothed studies were stored on
floppy disk or magnetic tape. The RVG-EF was determined
from the left anterior oblique projection using semiautomated
edge-detection algorithms, varying regions of interest through-
out the cardiac cycle, and background correction. Ejection
fraction was calculated in standard fashion: end-diastolic
counts 2 minus end-systolic counts/end-diastolic counts. Ra-
dionuclide studies were analyzed in the nuclear medicine
laboratories of each of the 50 SAVE clinical centers and their
component participating hospitals, where a wide variety of
commercially available computers and software was used to
measure RVG-EF. Nevertheless, although different software
was used in various laboratories, EF was determined according
to similar concepts and principles. Overreading of a randomly
selected group of studies for the purpose of quality control was
performed at the Yale University RVG Core Laboratory.
Contrast ventriculography. The decision to perform left
ventriculography as part of the catheterization procedure was
based on clinical indications and local practice in each cathe-
terization laboratory and was not mandated by the SAVE
protocol. Each analysis was carried out by one of three
experienced invasive cardiologists (G.L., G.F., S.S.).
The left ventricular silhouettes at end-diastole and end-
systole were traced onto a transparency film and digitized at a
resolution of 10 points per millimeter by using a digitizing
tablet interfaced to a personal computer. When extrasystoles
were present, care was taken to analyze a cardiac cycle at least
two beats after the last extrasystole. Computer-assisted analy-
sis provided LV volumes by the area-length (11) method in
358 patients in whom calibration for magnification correc-
tion was available. Thus, conventional, volume-based EF
could be calculated on only 52% of the study cohort. To
permit analysis of all patients who had undergone contrast
left ventriculography, we analyzed a surrogate, area-based
EF (Cath-EFa). Using traced systolic and diastolic areas
uncorrected for magnification the simple formula for Cath-
EFa is as follows:
Cath-EFa 5
~diastolic area 2 systolic area!
diastolic area
3 100
Statistical analyses. Baseline characteristics were exam-
ined with simple descriptive statistics. Validation of Cath-EFa
was made by assessing its linear correlation coefficient to
volumetric EF. Patients who had EF assessed by both methods
were divided into terciles according to their level of EF, with
the lowest level of EF corresponding to the first tercile and the
highest EF to the third tercile by each method. A bivariate
analysis of the predictive value of EF tercile for the combined
clinical end point of severe congestive heart failure or cardio-
vascular mortality was carried out for each technique using
one-way analysis of variance.
The independent predictive value of each technique for the
combined end point of each technique was assessed using the
Cox proportional hazards method (12). A model was con-
structed using Cath-EFa, RVG-EF, and previously reported
clinical (2,13,14) and coronary anatomic predictors of postin-
farct outcome as independent variables, and the combined end
points as the dependent variable. Finally, a 3 3 3 table was
constructed showing the clinical outcomes of patients in whom
there was a disagreement between techniques used to measure
EF.
Abbreviations and Acronyms
Cath-EFa 5 ejection fraction at catheterization measured by area,
not volume methodology
EF 5 ejection fraction
LV 5 left ventricle or left ventricular
MI 5 myocardial infarction
RVG 5 radionuclide ventriculography
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Results
Baseline characteristics. The average age of the study
cohort was 57 6 11 years (Table 1), and 83% of the cohort was
male. A history of prior MI was present in 34% of the patients
enrolled. Coronary angiograms were available on all 688
patients studied, and triple-vessel disease was present in 22%.
The average RVG-EF of the group was 32% 6 7. Most
(63.5%) patients had sustained an anterior-wall MI.
Validation of Cath-EFa. The linear correlation coefficient
of Cath-EFa with volumetric Cath-EF in 358 patients with
available LV volumes was 0.96 (p , 0.001) (Fig. 1). In contrast,
the correlation between Cath-EF and RVG-EF was 0.46 (p ,
0.001) in 358 patients; and between Cath-EFa and RVG-EF
0.42 (p , 0.001) in all 688 patients (Fig. 2).
Validation of RVG-EF measured at the clinical units. The
linear correlation coefficient of RVG-EF with RVG-EF (core)
was calculated in 326 studies that had undergone measurement
at the clinical site, and the core lab. The correlation coefficient
was 0.73 p , 0.001.
Correlation with clinical events. The RVG-EF was divided
into terciles. The first tercile was comprised of patients with an
RVG-EF of 30% or less (n 5 236). The second tercile included
patients with an RVG-EF between 31% and 36% (n 5 220).
The third tercile included patients with an RVG-EF over 36%
(n 5 232). There was a stepwise decrease in the incidence of
the combined endpoint in patients with higher RVG-EF
(RVG-EF tercile 1, 39.9%; tercile 2, 26.1%; and tercile 3,
15.6%; (p , 0.001).
Likewise, Cath-EFa was divided into terciles. The first
tercile included patients with Cath-EFa 38% or less (n 5 233),
and had an incidence of the combined endpoint of 40.7%. The
second tercile included patients with Cath-EFa between 38%
and 46% (n 5 238), and had an incidence of the combined end
point of 25.9%. The third tercile included patients with Cath-
EFa greater than 46% (n 5 256). This group had an incidence
of the combined end point of 11.6% (p , 0.001) (Fig. 3).
Patients whose RVG-EF was in the first tercile of RVG-EF,
but in the third tercile of Cath-EFa; or whose RVG-EF was in
the third tercile of RVG-EF, but in the first tercile of Cath-EFa
were labelled as discordant by 2 terciles, and comprised 11.1%
of the cases. In this small group of patients, the incidence of
the combined clinical end point was intermediate (19.5%)
between the highest EF tercile and lowest EF tercile clinical
event rates (Table 2).
Multivariate analyses. A multivariate model then was con-
structed to determine the independent predictors of the com-
bined clinical end point in this cohort. The results of a a Cox
regression analysis revealed that age (p , 0.001), hypertension
(p , 0.001), number of diseased vessels (p , 0.001), use of
beta-blockers (p 5 0.05), RVG-EF (p , 0.001), Cath-EFa
(p , 0.001) and captopril therapy (p 5 0.06) independently
predicted outcome. Gender, aspirin therapy, use of thrombo-
lytics, prior MI and diabetes mellitus were not found to be
significant predictors of the combined end point during the
average follow-up period of 3.5 years (Table 3).
Figure 1. Scattergram of area-based EF (Cath-
EFa) and volume-based EF (Cath-EF); R 5 0.96,
p , 0.001.
Table 1. Demographic and Clinical Characteristics of
Patients Enrolled
Age (mean 6 SD) 57 6 11 years
Gender (males) 82%
Race (white) 89%
Smoking 44%
Hypertension 37%
Diabetes mellitus 19%
Prior MI 34%
Triple vessel disease 22%
Anterior-wall MI 63.5%
RVG-EF 32% 6 7
Cath-EFa 42% 6 10
Cath-EFa 5 EF area by contrast ventriculography; RVG-EF 5 EF by
radionuclide ventriculography; SD 5 standard deviation.
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Discussion
The LV function is the principal determinant of outcome in
the post-MI period (13,15,16), and EF is one of the most
widely and clinically applicable measures of LV function. The
predominant modality used for the determination of ejection
fraction varies by institution. However, although the measure-
ment of EF initially was described using contrast left ventricu-
lography (17), noninvasive techniques have come into wide-
spread use. Nevertheless, regardless of the method, the
importance of an accurate estimation of the degree of LV
dysfunction in the post-MI period is of paramount importance
in the postthrombolytic era owing to its prognostic and thera-
peutic implications (18).
Among noninvasive techniques to measure EF, RVG is of
particular interest vis-a`-vis its comparability to contrast ven-
triculography. The measurement of EF with contrast ventricu-
lography requires geometric assumptions of ellipsoidal LV
Figure 3. Bar graphs showing the relationship between EF tercile
measured by either RVG (RVG-EF) or catheterization (Cath-EFa)
and the first occurrence of severe congestive heart failure (CHF) or
death. See text for EF boundaries defining terciles.
Figure 2. Scattergram of area-based EF (Cath-
EFa) and radionuclide ventriculographic EF
(RVG-EF); R 5 0.42, p , 0.001).
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shape. However, the measurement of EF by RVG is count-
based and may be less dependent on geometric assumptions.
Thus, the correlation of RVG to catheterization EF is of
clinical importance. Validation studies of EF by RVG have
reported correlations with Cath EF ranging from 0.80 to 0.92
(19–21,23). However, all reports have not been quite so
positive. For example, Manish et al. (22) reported a series of
cases in which agreement among echocardiographic EF, RVG-
EF, and angiographic EF ranged from 23% to 42%. An
important potential source of error when comparing the
techniques stems from the preferential contribution to the
overall counts of tracer nearest the chest wall. Because of
lower attenuation, patients with large akinetic anterolateral
walls or apices may have greater contribution to overall counts
from diseased areas, and hence an underestimation of EF.
We found a correlation between RVG-EF and cath-EFa of
0.42. Although the correlation was statistically significant, the
correlation coefficient is considerably lower than expected
based on the preponderance of published results. This discor-
dance may be related to the participation of many different
hospitals in the acquisition of RVG and catheterization data.
In general, prior studies have been reported from centers
specializing in validating radionuclide techniques (20,23). The
authors believe that participation in the present study by a
diverse group of operators represents a strength. These find-
ings reflect what the practicing physician is likely to encounter
when interpreting EFs measured with different techniques in
different hospitals.
Prior studies that have documented the importance of EF
in predicting clinical outcome have generally focused on a
single technique for each study, and have been unable to
compare the independent prognostic information yielded by
multiple techniques for measuring EF. In contrast, the SAVE
database provided a unique opportunity to compare the prog-
nostic abilities of RVG and catheterization EF in a subgroup
of 688 patients. As expected, each technique alone was an
excellent predictor of the primary end point of cardiovascular
mortality or congestive heart failure. The evidence of an
increased rate of adverse cardiovascular events in the group
with the lowest levels of EF by both techniques correlates well
with previous studies (24–27).
Although the combined end point of cardiovascular mortality
or congestive heart failure was well predicted by both techniques,
both RVG and Cath EFa were unexpectedly found to be inde-
pendent predictors of outcome. An interesting corollary to this
unexpected observation was present in the subgroup of patients in
whom EF was in the first (or third) tercile with one technique, and
in the third (or first) tercile with the other. In this small subgroup
of 11% of the cohort, if one technique were less accurate than the
other, then the expected result would be for the event rate to
reflect that of the technique which was most accurate. This,
however, was not observed.
In contrast, the outcome of patients with a 2-tercile dis-
agreement was intermediate, more closely reflecting those
patients in the middle terciles. For example, patients whose
Cath-EFa and RVG-EF were both in the third tercile had an
excellent outcome, with an incidence of CHF or death of 7%.
However, in a patient whose RVG-EF was in the first tercile,
and whose Cath-EFa was in the first tercile, prognosis was
intermediate, with an incidence of the combined end point of
20%. Unfortunately, the reason for this observation is less than
clear, but it may have to do with subtle differences in the
measurement of EF, LV volumes, and LV geometry by each
technique.
For example, the measurement of EF by RVG should carry
with it little information regarding LV volume or geometry.
However, catheterization EF, even when measured by the mod-
ified technique reported here, does correlate more strongly with
LV volumes and geometry than does RVG-EF. Thus, the phys-
iologic principle is correct that all EF measurements should be
the same. However, in practical terms each technique might
introduce additional data on LV function, which may modify its
ability to predict prognosis. Although the explanation for this
observation is tentative and not conclusive, the observation itself
is of clinical relevance for patients whose EF has been measured
by different techniques, with divergent results. It is clear from this
study that these patients have an intermediate prognosis.
Study limitations. The present study has several limita-
tions. Perhaps the most important is the shift in current
practice away from RVG measurement of EF toward a fre-
quently qualitative measurement with echocardiography. This
clinical shift limits the applicability of the present study.
However, the present study suggests a methodology for the
future assessment of the clinical importance of EF measure-
ment by echocardiography as compared with other techniques.
Table 2. Agreement Between Techniques (RVG-EF and Cath-EFa)
With Clinical End Points
% CHF Mortality*
p Value
1st Tercile
RVG-EF
2nd Tercile
RVG-EF
3rd Tercile
RVG-EF
1st Tercile Cath-EFa 46% n 5 56 45% n 5 31 19% n 5 9 p , 0.001
2nd Tercile Cath-EFa 34% n 5 22 21% n 5 21 24% n 5 21 p , 0.001
3rd Tercile Cath-EFa 20% n 5 6 15% n 5 13 7% n 5 8 p , 0.001
Cath-EFa 5 EF area by contrast ventriculography; RVG-EF 5 EF by
radionuclide ventriculography. *Development of congestive heart failure or
cardiovascular mortality.
Table 3. Cox Regression Analysis Dependent Variable:
CHF or Mortality
Independent
Variables
Odds
Ratio 95% CI
Wald
Chi-Square p Value
Age 1.01 1.00–1.03 4.43 0.03
Hypertension 1.78 1.32–2.40 14.58 , 0.001
Killip class 1.48 1.10–2.00 6.66 0.05
No. of Diseased Vessels 1.51 1.26–1.81 20.24 , 0.001
Cath-EFa 0.95 0.92–0.96 20.99 , 0.001
RVG-EF 0.96 0.94–0.97 15.28 , 0.001
Gender, prior MI, use of thrombolytics and diabetes were not statistically
significant.
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Another important limitation is a statistical consideration that
likely leads an underestimation of true correlation between
techniques used to measure EF. The SAVE study, by design,
systematically excluded patients with an RVG EF above 40%,
while not basing any exclusion criteria on catheterization EF.
This narrowed range of RVG EF reduces the spread of EF
measurement and, hence, diminishes the measured correlation
coefficient.
Conclusions. In the postmyocardial infarction period, ejec-
tion fraction by radionuclide ventriculography and ventriculog-
raphy by cardiac catheterization are valuable tools in the
risk-stratification of patients. The results of the present study
suggest that significant disagreement in measurements may
occur when utilizing different techniques. When clinical cir-
cumstances and conditions are inconsistent with the measured
ejection fraction, remeasurement by another method will allow
more accurate risk stratification. The optimal utilization and
interpretation of EF by RVG and contrast ventriculography
offer an effective and reliable way of stratifying patients and
contribute to the management of the postmyocardial infarction
population.
The authors acknowledge the expert secretarial assistance of Mrs. Lori Saint-
Thomas.
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